ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4971ometendo-4971Research ArticleСтатьиArticlesЦентральные механизмы, регулирующие энергетический обмен, и сибутраминCentral mechanisms regulating energy metabolism and sibutramineDalantaevaN S
аспирант отделения нейроэндокринологии и остеопатий
nsdalantaeva@gmail.comPigarovaE A
к.м.н., ст.н.с. отделения нейроэндокринологии и остеопатий
kpigarova@gmail.comDzeranovaL K
д.м.н., гл.н.с. отделения нейроэндокринологии и остеопатий
-20121509201293№3 (2012)3336Copyright © Dalantaeva N.S., Pigarova E.A., Dzeranova L.K., 20122012Dalantaeva N.S., Pigarova E.A., Dzeranova L.K.Dalantaeva N.S., Pigarova E.A., Dzeranova L.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4971ReferencesMcNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs. 1998;56(6):1093–1124.McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs. 1998;56(6):1093–1124.Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc. Health Risk Manag. 2009;5(1):441–452.Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc. Health Risk Manag. 2009;5(1):441–452.Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes. Res. 1998;6(Suppl 2):51S–209S.Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes. Res. 1998;6(Suppl 2):51S–209S.Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369(9555):71–77.Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369(9555):71–77.Schwartz MW, Woods SC, Porte D, Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404(6778):661–671.Schwartz MW, Woods SC, Porte D, Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404(6778):661–671.Halford JC, Harrold JA. Neuropharmacology of human appetite expression. Dev. Disabil. Res. Rev. 2008;14(2):158–164.Halford JC, Harrold JA. Neuropharmacology of human appetite expression. Dev. Disabil. Res. Rev. 2008;14(2):158–164.Garfield A S, Heisler L K. Pharmacological targeting of the serotonergic system for the treatment of obesity. J. Physiol. 2009;587(Pt 1):49–60.Garfield A S, Heisler L K. Pharmacological targeting of the serotonergic system for the treatment of obesity. J. Physiol. 2009;587(Pt 1):49–60.Zanella MT, Ribeiro Filho FF. Emerging drugs for obesity therapy. Arq. Bras. Endocrinol. Metab. 2009;53(2):271–280.Zanella MT, Ribeiro Filho FF. Emerging drugs for obesity therapy. Arq. Bras. Endocrinol. Metab. 2009;53(2):271–280.Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol. Ther. 2009;124(1):44–56.Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol. Ther. 2009;124(1):44–56.Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006;443(7109):289–295.Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006;443(7109):289–295.Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann. Intern. Med. 2005;143(5):380–385.Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann. Intern. Med. 2005;143(5):380–385.Jandacek RJ, Woods SC. Pharmaceutical approaches to the treatment of obesity. Drug Discov. Today. 2004;9(20):874–880.Jandacek RJ, Woods SC. Pharmaceutical approaches to the treatment of obesity. Drug Discov. Today. 2004;9(20):874–880.Araújo JR, Martel F. Sibutramine effects on central mechanisms regulating energy homeostasis. Curr Neuropharmacol. 2012 Mar;10(1):49–52.Araújo JR, Martel F. Sibutramine effects on central mechanisms regulating energy homeostasis. Curr Neuropharmacol. 2012 Mar;10(1):49–52.Figlewicz DP. Endocrine regulation of neurotransmitter transporters. Epilepsy Res. 1999;37(3):203–210.Figlewicz DP. Endocrine regulation of neurotransmitter transporters. Epilepsy Res. 1999;37(3):203–210.Finer N. Sibutramine: its mode of action and efficacy. Int. J. Obes. Relat. Metab. Disord. 2002;26(Suppl 4):S29–33.Finer N. Sibutramine: its mode of action and efficacy. Int. J. Obes. Relat. Metab. Disord. 2002;26(Suppl 4):S29–33.Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr. Rev. 1999;20(6):805–875.Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr. Rev. 1999;20(6):805–875.Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol. Rev. 2007;59(2):151–184.Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol. Rev. 2007;59(2):151–184.Fernstrom JD, Choi S. The development of tolerance to drugs that suppress food intake. Pharmacol. Ther. 2008;117(1):105–122.Fernstrom JD, Choi S. The development of tolerance to drugs that suppress food intake. Pharmacol. Ther. 2008;117(1):105–122.Boozer CN, Leibel RL, Love RJ, Cha MC, Aronne LJ. Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats. Metabolism. 2001;50(8):889–893.Boozer CN, Leibel RL, Love RJ, Cha MC, Aronne LJ. Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats. Metabolism. 2001;50(8):889–893.
The authors declare that there are no conflicts of interest present.